AGIO - Company ID 0001439222
AGIOS PHARMACEUTICALS, INC. (AGIO) reported net income of -$413.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$413.00M | -161.3% |
| FY 2024 | $674.00M | +291.5% |
| FY 2023 | -$352.00M | -51.7% |
| FY 2022 | -$232.00M | -114.5% |
| FY 2021 | $1.60B | +590.3% |
| FY 2020 | -$327.37M | +20.4% |
| FY 2019 | -$411.47M | -18.9% |
| FY 2018 | -$346.03M | -10.0% |
| FY 2017 |
AGIOS PHARMACEUTICALS, INC. (AGIO) reported net income of -$413.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2025, AGIOS PHARMACEUTICALS, INC.'s net income declined from -$23.71M to -$413.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$314.67M |
| -58.5% |
| FY 2016 | -$198.47M | -68.6% |
| FY 2015 | -$117.73M | -120.0% |
| FY 2014 | -$53.50M | -35.8% |
| FY 2013 | -$39.41M | -96.0% |
| FY 2012 | -$20.10M | +15.2% |
| FY 2011 | -$23.71M | - |